hepatocellular carcinoma

Objective. To determine the most important prognostic factors for survival in patients with hepatocellular carcinoma (HCC).

Introduction. Hepatocellular carcinoma is one of the most prevalent cancers in the world and for less than 30-40% of patients radical treatment measures can be used. When such treatment options are not viable, systemic biological therapy with Sorafenib can be used. Sorafenib is a kinase inhibitor, that inhibits tumour cell proliferation and angiogenesis. The aim of this study is to determine treatment with Sorafenib efficacy depending on patients hepatic condition.

Objectives. To determine the correlation of alpha fetoprotein (AFP) with tumor size and the number of tumors in hepato­cellular carcinoma (HCC).